{
  "abstract": "Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor, frequently induces hypercholesterolemia and hypertriglyceridemia, but longitudinal qualitative lipoprotein changes remain incompletely characterized. We describe a 52-year-old woman with ALK-rearranged non-small cell lung cancer who developed persistent dyslipidemia despite lipid-lowering therapy. Before lorlatinib, total cholesterol was 164 mg/dL (SI [International System of Units]: 4.24 mmol/L) (reference range, 148-248 mg/dL [SI: 3.83-6.41 mmol/L]), low-density lipoprotein (LDL) cholesterol was 52 mg/dL (SI: 1.34 mmol/L) (reference range, 65-139 mg/dL [SI: 1.68-3.59 mmol/L]), and triglycerides were 54 mg/dL (SI: 0.61 mmol/L) (reference range, 30-117 mg/dL [SI: 0.34-1.32 mmol/L]). Within 3 weeks after lorlatinib initiation, these increased to 340, 245, and 166 mg/dL, respectively. Longitudinal profiling showed persistent apolipoprotein B (ApoB) elevation, increased oxidized LDL, and a prominent pre-β-lipoprotein fraction. Subclinical hypothyroidism was later detected, and pitavastatin was switched to rosuvastatin. This case highlights the potential value of ApoB and qualitative lipid assessment during prolonged lorlatinib therapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka 530-8480, Japan.",
    "Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Kimitaka Shibue",
      "orcid": "0000-0002-4576-4739"
    },
    {
      "affs": [
        1
      ],
      "name": "Kei Kunimasa"
    },
    {
      "affs": [
        0
      ],
      "name": "Akihiro Hamasaki"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5aa8br93nvnkr.bib",
  "cited_by": 0,
  "doi": "10.1210/jcemcr/luag324",
  "fulltext_url": "https://europepmc.org/articles/PMC13687888",
  "id": "5aa8br93nvnkr",
  "issns": [
    "2755-1520"
  ],
  "landing_url": "https://europepmc.org/article/MED/42923625",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2746|Lipoproteins and Cardiovascular Health"
    ]
  ],
  "openalex": "W7223185153",
  "pdf_url": "https://europepmc.org/articles/PMC13687888?pdf=render",
  "pmcid": "PMC13687888",
  "pmid": "42923625",
  "published": "2026-10-22",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/5aa8br93nvnkr.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:33Z",
      "native_id": "MED:42923625",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42923625"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Lipoproteins and Cardiovascular Health",
      "subfield": "surgery"
    }
  ],
  "title": "Persistent atherogenic lipoprotein changes during lorlatinib therapy.",
  "title_text": "Persistent atherogenic lipoprotein changes during lorlatinib therapy.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:33Z",
  "url": "https://research.draconitic.com/paper/5aa8br93nvnkr",
  "venue": "JCEM case reports",
  "versions": []
}